Search - tctmd.com

Displaying 1 - 20 of 157

Sort: Relevancy | Date

CELEBRATE: Zalunfiban, a Novel Glycoprotein IIb/IIIa Inhibitor, Helps in STEMI

News Conference News AHA 2025

CELEBRATE: Zalunfiban, a Novel Glycoprotein IIb/IIIa Inhibitor, Helps in STEMI

Michael O'Riordan

November 11, 2025

What Makes MedTech Great—or Not—and Envisioning Its Future

News Conference News TCT 2025

What Makes MedTech Great—or Not—and Envisioning Its Future

November 04, 2025

HI-PRO: Oral Apixaban for 1 Year Protective, Safe in Provoked VTE Patients

News Conference News ESC 2025

HI-PRO: Oral Apixaban for 1 Year Protective, Safe in Provoked VTE Patients

September 01, 2025

AQUATIC: More Than 6 Months After PCI, Don’t Use Aspirin With OAC

News Conference News ESC 2025

AQUATIC: More Than 6 Months After PCI, Don’t Use Aspirin With OAC

September 01, 2025

Studies Spotlight Safety Concerns With Pulsed-Field Ablation for AF

News Conference News HRS 2025

Studies Spotlight Safety Concerns With Pulsed-Field Ablation for AF

May 05, 2025

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

News Conference News ACC 2025

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

Michael O'Riordan

March 29, 2025

WARRIOR: No Clear Answers on How to Best Treat INOCA

News Conference News ACC 2025

WARRIOR: No Clear Answers on How to Best Treat INOCA

Yael L. Maxwell

March 29, 2025

Compared with PV Isolation Alone, AI-Guided Ablation Lowers AF at 12 Months

News Conference News

NOW PUBLISHED: Compared with PV Isolation Alone, AI-Guided Ablation Lowers AF at 12 Months

Yael L. Maxwell

February 18, 2025

Electrical Brain Stimulation Fails to Improve Poststroke Recovery

News Conference News ISC 2025

Electrical Brain Stimulation Fails to Improve Poststroke Recovery

February 10, 2025

STS Experts Tackle Need For Women-Only Trials in Surgery

News Conference News STS 2025

STS Experts Tackle Need For Women-Only Trials in Surgery

Yael L. Maxwell

January 29, 2025

OPTION: LAAO Matches Up to DOACs After Ablation, but Questions Remain

News Conference News AHA 2024

OPTION: LAAO Matches Up to DOACs After Ablation, but Questions Remain

November 18, 2024

Rivaroxaban Doesn’t Cut Cognitive Decline, Stroke, or TIA in Younger AF Patients

News Conference News AHA 2024

Rivaroxaban Doesn’t Cut Cognitive Decline, Stroke, or TIA in Younger AF Patients

November 16, 2024

First-line Catheter Ablation Works for Post-MI VT Suppression: VANISH2

News Conference News AHA 2024

First-line Catheter Ablation Works for Post-MI VT Suppression: VANISH2

November 16, 2024

SUMMIT: Tirzepatide ‘Huge Win’ for HFpEF Patients With Obesity

News Conference News AHA 2024

SUMMIT: Tirzepatide a ‘Huge Win’ for HFpEF Patients With Obesity

Michael O'Riordan

November 16, 2024

PAD Patients’ Views on Decisions and Outcomes Hinge on Sex, Race/Ethnicity: ELEGANCE

News Conference News TCT 2024

PAD Patients’ Views on Decisions and Outcomes Hinge on Sex, Race/Ethnicity: ELEGANCE

November 04, 2024

STEEER-AF: Educating Healthcare Workers Improves Adherence to Guidelines

News Conference News ESC 2024

STEEER-AF: Educating Healthcare Workers Improves Adherence to Guidelines

September 06, 2024

Asundexian for AF? More Details on the Sinking of OCEANIC-AF

News Conference News ESC 2024

Asundexian for AF? More Details on the Sinking of OCEANIC-AF

September 02, 2024

Treatment Gaps Abound in Heart Failure but Can Be Closed, Studies Show

News Conference News ESC Heart Failure 2024

Treatment Gaps Abound in Heart Failure but Can Be Closed, Studies Show

Michael O'Riordan

May 21, 2024

Long-Awaited RCT Data Show Survival Benefit With Impella CP: DanGer Shock

News Conference News ACC 2024

Long-Awaited RCT Data Show Survival Benefit With Impella CP: DanGer Shock

April 07, 2024

Most HFrEF Patients Eligible for Quadruple Therapy, but Few Get It

News Conference News ACC 2024

Most HFrEF Patients Eligible for Quadruple Therapy, but Few Get It

Michael O'Riordan

March 27, 2024

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.